ATTO Stock Price, Performance & Company Data

13:30

15:10

16:45

18:25

20:00

About Attovia Therapeutics

Ticker

$ATTO

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

San Carlos, United States

Website

www.attovia.com

ATTO Metrics

BasicAdvanced

$877m

-$1.71

Bulls say / Bears say

Interim Phase 1b data for ATTO-1310 demonstrated rapid, deep itch relief (≥4-point PP-NRS improvement in 65% of chronic pruritus and 44% of high-itch AD patients at week 4) with predominantly Grade 1/2 AEs and no SAEs, supporting quarterly dosing and underscoring clinical potential (SEC Prospectus)

The proprietary ATTOBODY platform has generated ATTO-2306, a bispecific targeting IL-13 and IL-31, which in preclinical studies exhibited high potency, low projected immunogenicity, and a non-human primate half-life translating to an expected 75-day human half-life, enabling infrequent dosing (SEC Prospectus)

The August 2026 IPO raised $289 million by pricing 17 million shares at $17, providing a substantial cash runway to fund ongoing and planned clinical trials across its lead programs (Axios)

Phase 2 proof-of-concept data for ATTO-1310 and ATTO-2306 is still pending, leaving clinical validation and regulatory approval timelines uncertain and exposing the company to development risk (SEC Prospectus)

Attovia’s future growth is heavily dependent on the successful development and commercialization of its lead candidates ATTO-1310, ATTO-2306 and ATTO-1091; failure of any could materially impair the company’s prospects (SEC Prospectus)

IND-enabling studies for ATTO-2306 are ongoing, but a Phase 1 trial is not expected to commence until the first half of 2027, delaying key catalyst events and potential value inflection points (SEC Prospectus)

Data summarised monthly by Lightyear AI. Last updated on 6 Aug 2026.

ATTO Financial Performance

Revenues and expenses

Income statement
QuarterlyAnnual	Q3 24	QoQ growth
Revenue	$37bn	-39.75%
Net income	$45bn	107.52%
Profit margin	37.65%	6.78%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

The August 2026 IPO raised $289 million by pricing 17 million shares at $17, providing a substantial cash runway to fund ongoing and planned clinical trials across its lead programs (Axios)

Data summarised monthly by Lightyear AI. Last updated on 6 Aug 2026.

About Attovia Therapeutics

Ticker

Employees

ATTO Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

ATTO Financial Performance

Income Statement

Buy $ATTO

Lightyear

Legal

Work with us

Bulls say / Bears say

Attovia Therapeutics/$ATTO

About Attovia Therapeutics

Ticker

Employees

ATTO Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

ATTO Financial Performance

Income Statement

Bulls say / Bears say